Peer-reviewedCC BY-NC-NDnpj Breast Cancer
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
Abstract
In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned. Here, we provide further clarification on several aspects of this clinically relevant discussion.
Related
- Analyzing globin gene variation in gnomAD: implications for variant interpretation in hemoglobinopathies
- An immunosuppression imaging gauge prospectively predicts metastatic progression and immunotherapy resistance in breast cancer
- The clinical spectrum of MECP2 variants in males: a multicenter Turkish cohort of 22 probands, with implications for diagnosis and variant interpretation
- Molecular Screening for Potential Resistance to Toxic Invasive Prey: Implications for Island Conservation
- Verticillium Wilt Resistance in Solanaceous Crops: Genetic Resources, Grafting-Mediated Systemic Defense, and Implications for Productivity
BibTeX
@article{bidard2026serena6,
title = {{SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer}},
author = {François-Clement Bidard and Carlos Barrios and Giampaolo Bianchini and Adam M. Brufsky and Stephen Chia and Javier Cortes and Massimo Cristofanilli and Giuseppe Curigliano and Shaheenah Dawood and Peter A. Fasching and Lorenzo Gerratana and Antonio Giordano and Michail Ignatiadis and Hiroji Iwata and Wolfgang Janni and Elgene Lim and Kevin Kalinsky and Cynthia X. Ma and Erica L. Mayer and Arielle J. Medford and Jason A. Mouabbi and Joyce O'Shaughnessy and Yeon Hee Park and Javier Pascual and Pedram Razavi and Sarah Sammons and José Luis Sandoval and Luisana Sisca and Paolo Tarantino and Seth A. Wander and Gustavo Werutsky and Nicholas A. Turner},
journal = {npj Breast Cancer},
year = {2026},
month = nov,
doi = {10.1038/s41523-026-00967-4},
url = {https://hal.science/hal-05851611v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
AU - François-Clement Bidard
AU - Carlos Barrios
AU - Giampaolo Bianchini
AU - Adam M. Brufsky
AU - Stephen Chia
AU - Javier Cortes
AU - Massimo Cristofanilli
AU - Giuseppe Curigliano
AU - Shaheenah Dawood
AU - Peter A. Fasching
AU - Lorenzo Gerratana
AU - Antonio Giordano
AU - Michail Ignatiadis
AU - Hiroji Iwata
AU - Wolfgang Janni
AU - Elgene Lim
AU - Kevin Kalinsky
AU - Cynthia X. Ma
AU - Erica L. Mayer
AU - Arielle J. Medford
AU - Jason A. Mouabbi
AU - Joyce O'Shaughnessy
AU - Yeon Hee Park
AU - Javier Pascual
AU - Pedram Razavi
AU - Sarah Sammons
AU - José Luis Sandoval
AU - Luisana Sisca
AU - Paolo Tarantino
AU - Seth A. Wander
AU - Gustavo Werutsky
AU - Nicholas A. Turner
PY - 2026
DA - 2026/11/04
JO - npj Breast Cancer
DO - 10.1038/s41523-026-00967-4
UR - https://hal.science/hal-05851611v1
AB - In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned. Here, we provide further clarification on several aspects of this clinically relevant discussion.
SN - 2374-4677
ER -